News Overview

UPM Biomedicals


UPM Biomedicals makes products for life science and clinical uses based on our patented nanofibrillar cellulose technology from birch wood pulp. Our clinical products are manufactured under ISO 13485 quality management system. Our animal-free biomaterial finds applications in 3D cell culture, drug discovery and screening, cell storage and transportation, 3D bioprinting, tissue engineering, advanced wound care, implants, personalized medicine and novel drug formulations. We also provide cell culture protocol development and workflow integration support services for our life science customers in adopting our technology. We are part of UPM Corporation that provides renewable solutions for various end uses. We employ 17,200 people worldwide and our annual sales are approximately EUR 11.7 billion.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.